Recognizing the conjunction between SHP-2 and cancer together with our findings that SHP-2 is responsible for harmful consequences of diabetes mellitus, pharmacological SHP-2 inhibition could also act as a preventive therapy against the development of cancer in diabetic patients. Here, PTPN11 is linked to cancer.